Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101 NA COMPLETED

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Details

Lead sponsor	Mitchell Grayson
Phase	NA
Status	COMPLETED
Enrolment	25
Start date	Wed Sep 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Nasal Allergy

Interventions

• Nasal lavage
• Nasal allergen challenge
• Epicutaneous skin testing
• Peripheral blood
• Montelukast 10Mg Tablet
• Placebo Oral Tablet

Countries

United States